|
|
|
|
EUROs for $1 DOLLAR: 3 MONTHS |
 | |
|
Receive FRESH Daily Updates for 17 StockRing Reports for $30/month !!!
1. Dow Jones Index - 30 Stocks on 11/12/2009: Buy
93% or 28 Hold
7% or 2 Sell
0% or 0 stocks
2. World Markets - 72 Indexes on 11/11/2009: Buy
63% or 44 Hold
21% or 15 Sell
16% or 11 indexes
3. Best Brands - 200 stocks on 11/12/2009: Buy
76% or 152 Hold
17% or 33 Sell
7% or 14 stocks
4. Hot News - 200 stocks on 11/8/2009: Buy
47% or 93 Hold
23% or 46 Sell
30% or 60 stocks
5. Big Movers - 200 stocks on 11/14/2009: Buy
69% or 137 Hold
23% or 47 Sell
8% or 15 stocks
6. Top Hitters - 200 stocks on 11/11/2009: Buy
77% or 153 Hold
15% or 31 Sell
8% or 15 stocks
7. S&P 500 Index - 500 Stocks on 7/21/2009:
Buy
68% or 341 Hold
21% or 106 Sell
11% or 53 stocks
8. S&P 400 Mid Cap - 400 Stocks on 7/21/2009: Buy
73% or 292 Hold
15% or 61 Sell
12% or 47 stocks
9. S&P 600 Small Cap - 600 Stocks on 4/18/2009: Buy
66% or 395 Hold
26% or 156 Sell
8% or 49 stocks
10. Nasdaq Telecom - 164 Stocks on 7/24/2009: Buy
49% or 81 Hold
35% or 56 Sell
16% or 27 stocks
11. Nasdaq Computer - 440 Stocks on 7/22/2009: Buy
60% or 263 Hold
26% or 115 Sell
14% or 62 stocks
12. Nasdaq Finance - 180 Stocks on 7/24/2009: Buy
61% or 109 Hold
6% or 12 Sell
33% or 59 stocks
13. NYSE International - 100 Stocks on 7/21/2009: Buy
58% or 58 Hold
34% or 34 Sell
8% or 8 stocks
14. Legg Mason Mutual - 346 Funds on 10/6/2009: Buy
38% or 133 Hold
51% or 176 Sell
11% or 37 funds
15. T. Row Price Mutual - 161 Funds on 10/6/2009: Buy
52% or 84 Hold
46% or 73 Sell
2% or 4 funds
16. London FTSE 100 - 94 Stocks on 4/1/2009: Buy
20% or 19 Hold
50% or 47 Sell
30% or 28 stocks
17. Canada Toronto - 209 Stocks on 4/18/2009: Buy
53% or 111 Hold
34% or 70 Sell
13% or 28 stocks
TOTAL RATINGS:
Buy
60% or 2493 Hold
27% or 1080 Sell
13% or 517 stocks
Video: 6-24-09 - Dow 30 stocks Buy-Sell-Hold Ratings
11/15/2009 Sunday, November 15, 2009 (Irvine, California) Today StockRing.com Recommendation is to "SUPER BUY"for Vertex Pharmaceut (NASDAQ:VRTX) Stock.
VRTX stock opening price was $40.83 per share.
Current price of NASDAQ:VRTX Stock is $40.58 per share
and it is
$-0.26, (-0.64%) today
and it was trading in the daily range of $40.45 - 41.05 per share.
Current Bid Price for (NASDAQ:VRTX) stock is $39.00 and the Ask Price is $0.00. In the last 52 weeks
VRTX stock was trading in the range of $19.87 - 41.75. 50-Day Moving Average for (NASDAQ:VRTX) stock is
$35.6262 and 200-Day Moving Average is $34.0678. On average analysts predict that One Year Target Estimated price for
(NASDAQ:VRTX) stock is $42.75.
Vertex Pharmaceut (NASDAQ:VRTX) Market capitalization is $7.341B. (NASDAQ:VRTX) stock average daily volume is
2,101,180 shares per day.
However, on last trading session of Nov 13, 2009
VRTX stock traded 1,982,090 shares.
Also The Short Ratio for (NASDAQ:VRTX) stock is 8.00.
On previous trading session VRTX Stock closed at $40.84 per share.
Last year Vertex Pharmaceut (NASDAQ:VRTX) before taxes (EBITDA) (ttm) earned $-563.6M on total revenue of $100.8M.
Earnings Per Share - EPS (ttm) for VRTX stock is -3.815.
Thus, (NASDAQ:VRTX) Stock Price/Sales (ttm) ratio is 73.28 and Price/Book (mrq) ratio is 12.14.
(NASDAQ:VRTX) Stock does NOT PAY any dividend.
So at this time (NASDAQ:VRTX) Stock maintains Trailing Annual Dividend Rate at 0.00
.
StockRing Recommendations for Vertex Pharmaceut (NASDAQ:VRTX) Stock are updated daily here
http://www.StockRing.com/sr/StockDetail.asp?StockName=VRTX
If you would like to receive Buy-Sell-Hold ratings for over 50,000 stocks, mutual funds, and ETFs go to StockRing web site: http://www.StockRing.com.
|
VRTX Stock Charts: 1d 5d 3m 6m 1y 2y 5y Max News
Options! More Info
 | |
| 1 Year Dow Jones Chart |
1 Year S&P 500 Chart |
 |
 |
| 1 Year Nasdaq Chart |
1 Year Canada Chart |
 |
 |
|
| |
| 5 Days Dow Jones Chart |
5 Days S&P 500 Chart |
 |
 |
| 5 Days Nasdaq Chart |
5 Days Canada Chart |
 |
 |
|
VRTX Stock Charts: 1d 5d 3m 6m 1y 2y 5y Max News
Options! More Info
|
| Last Trade: |
40.58 |
| Trade Time: |
Nov 13 |
| Change: |
-0.26, (-0.64%) |
| Prev Close: |
40.84 |
| Open: |
40.83 |
| Bid: |
39.00 |
| Ask: |
0.00 |
| 1y Target Est: |
$42.75 |
| 50-Day Moving Average: |
35.6262 |
200-Day Moving Average:
|
34.0678 |
| Short Ratio: |
8.00 |
| Trailing Annual Dividend Rate: |
0.00
|
|
| Day's Range: |
40.45 - 41.05 |
| 52wk Range: |
19.87 - 41.75 |
| Volume: |
1,982,090 |
| Avg Vol: |
2,101,180 |
| Market Cap: |
7.341B |
| P/E (ttm): |
N/A |
| EPS (ttm): |
-3.815 |
| Div & Yield: |
0.00 (N/A%) |
| Revenue (ttm): |
100.8M |
| Earnings before Tax (EBITDA) (ttm): |
-563.6M |
| Price/Sales (ttm): |
73.28 |
| Price/Book (mrq): |
12.14 |
|
Receive FRESH Daily Updates for 17 StockRing Reports for $30/month !!!
|
|
|
|
EUROs for $1 DOLLAR: 3 MONTHS | |
| |
|
Vertex Pharmaceuticals Incorpor (NasdaqGS: VRTX) Company Information
Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, MA 02139-4242
United States - Map
Phone: 617-444-6100
Fax: 617-576-2109
Web Site: http://www.vrtx.com
Vertex Pharmaceuticals Incorpor (NasdaqGS: VRTX) DETAILS
Vertex Pharmaceuticals Incorpor (NasdaqGS: VRTX) Index Membership: S&P 400 MidCap
S&P 1500 Super Comp
Nasdaq 100
Vertex Pharmaceuticals Incorpor (NasdaqGS: VRTX) Sector: Healthcare
Vertex Pharmaceuticals Incorpor (NasdaqGS: VRTX) Industry: Drug Manufacturers - Other
Vertex Pharmaceuticals Incorpor (NasdaqGS: VRTX) Full Time Employees: 1,310
Vertex Pharmaceuticals Incorpor (NasdaqGS: VRTX) BUSINESS SUMMARY
Vertex Pharmaceuticals Incorporated engages in the discovery, development, and commercialization of small molecule drugs for the treatment of serious diseases worldwide. Its product pipeline includes Telaprevir, a Phase III clinical trial product for the treatment of hepatitis C virus (HCV) infection; VX-813, a Phase Ia clinical trial product for chronic HCV infection; VX-985, which is under preclinical trails for chronic HCV infection; VX-770, a Phase IIa clinical trial candidate for the treatment of Cystic fibrosis; VX-809, a Phase Ib clinical trial product for the treatment of Cystic fibrosis; VX-509, a Phase Ia clinical trial product for immune-mediated inflammatory diseases; MK-5108 (VX-689), a Phase I clinical trial product for the treatment of cancer; and AVN-944(VX-944), which is in Phase 2 clinical trial for the treatment of cancer. The company also has development and commercial rights to VX-702 for the treatment of rheumatoid arthritis and other inflammatory diseases. It has collaboration agreements with Janssen Pharmaceutica, N.V.; Mitsubishi Tanabe Pharma Corporation; Cystic Fibrosis Foundation Therapeutics Incorporated; Merck & Co., Inc.; Avalon Pharmaceuticals, Inc.; GlaxoSmithKline plc.; and Bend Research Inc. Vertex Pharmaceuticals was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Vertex Pharmaceuticals Incorpor (NasdaqGS: VRTX) KEY EXECUTIVES, SALARIES and BONUSES
Mr. Matthew Emmens , Age: 57
Chairman, Chief Exec. Officer and Pres Salary: $ 64.00K Bonus: N/A
Dr. Joshua S. Boger Ph.D., Age: 57
Founder and Exec. Director Salary: $ 1.69M Bonus: $ 2.76M
Mr. Ian F. Smith C.P.A., A.C.A., Age: 43
Chief Financial Officer and Exec. VP Salary: $ 835.00K Bonus: $ 1.55M
Mr. Kenneth S. Boger M.B.A., J.D., Age: 62
Sr. VP, Sec. and Gen. Counsel Salary: $ 713.00K Bonus: $ 0
Dr. Peter R. Mueller Ph.D., Age: 52
Chief Scientific Officer, Exec. VP of Global Research & Developement and Member of the Scientific Advisory Board Salary: $ 841.00K Bonus: $ 227.00K
|
1. Dow Jones Index - 30 Stocks on 11/12/2009: Buy
93% or 28 Hold
7% or 2 Sell
0% or 0 stocks
2. World Markets - 72 Indexes on 11/11/2009: Buy
63% or 44 Hold
21% or 15 Sell
16% or 11 indexes
3. Best Brands - 200 stocks on 11/12/2009: Buy
76% or 152 Hold
17% or 33 Sell
7% or 14 stocks
4. Hot News - 200 stocks on 11/8/2009: Buy
47% or 93 Hold
23% or 46 Sell
30% or 60 stocks
5. Big Movers - 200 stocks on 11/14/2009: Buy
69% or 137 Hold
23% or 47 Sell
8% or 15 stocks
6. Top Hitters - 200 stocks on 11/11/2009: Buy
77% or 153 Hold
15% or 31 Sell
8% or 15 stocks
7. S&P 500 Index - 500 Stocks on 7/21/2009:
Buy
68% or 341 Hold
21% or 106 Sell
11% or 53 stocks
8. S&P 400 Mid Cap - 400 Stocks on 7/21/2009: Buy
73% or 292 Hold
15% or 61 Sell
12% or 47 stocks
9. S&P 600 Small Cap - 600 Stocks on 4/18/2009: Buy
66% or 395 Hold
26% or 156 Sell
8% or 49 stocks
10. Nasdaq Telecom - 164 Stocks on 7/24/2009: Buy
49% or 81 Hold
35% or 56 Sell
16% or 27 stocks
11. Nasdaq Computer - 440 Stocks on 7/22/2009: Buy
60% or 263 Hold
26% or 115 Sell
14% or 62 stocks
12. Nasdaq Finance - 180 Stocks on 7/24/2009: Buy
61% or 109 Hold
6% or 12 Sell
33% or 59 stocks
13. NYSE International - 100 Stocks on 7/21/2009: Buy
58% or 58 Hold
34% or 34 Sell
8% or 8 stocks
14. Legg Mason Mutual - 346 Funds on 10/6/2009: Buy
38% or 133 Hold
51% or 176 Sell
11% or 37 funds
15. T. Row Price Mutual - 161 Funds on 10/6/2009: Buy
52% or 84 Hold
46% or 73 Sell
2% or 4 funds
16. London FTSE 100 - 94 Stocks on 4/1/2009: Buy
20% or 19 Hold
50% or 47 Sell
30% or 28 stocks
17. Canada Toronto - 209 Stocks on 4/18/2009: Buy
53% or 111 Hold
34% or 70 Sell
13% or 28 stocks
TOTAL RATINGS:
Buy
60% or 2493 Hold
27% or 1080 Sell
13% or 517 stocks
Vertex Turns $109M Debt Into Stock
Xconomy - Nov 10, 2009
Vertex Pharmaceuticals, the Cambridge, MA-based developer of treatments for hepatitis C, said today that investors who hold about $109 million worth of debt securities have converted those ...
Aw, A Success
GenomeWeb Daily News - Nov 6, 2009
A Forbes article entitled, “Genomics: No Longer A Failure,†says that Human Genome Sciences and Vertex Pharmaceuticals are finally living up to the hype promised during Human Genome Project. Human ...
|
|
Vertex Turns $109M Debt Into StockXconomyThe debtholders who are accepting stock will now get 4.8 million shares of Vertex (NASDAQ: VRTX). The company's shares have more than doubled in value to ... |
|
|
No comments:
Post a Comment